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PREDICTING POSTPROCEDURE BLEEDING IN 
LIVER DISEASE 
McVay PA, Toy PTCY. Lack of increased bleeding after 
liver biopsy in patients with mild hemostatic abnormal- 
ities. Am J Clin Pathol 1990;94:747-753. 
ABSTRACT 
Prophylactic transfusions of fresh frozen plasma and 
platelets are sometimes given to patients with mild 
elevations in prothrombin time (PT) and partial 
thromboplastin time (PTT) and mild thrombocyto- 
penia before percutaneous liver biopsy. To determine 
whether PTs and PTTs 1.1-1.5 times midrange normal 
levels and platelet counts 50-99 x lOe/L are associated 
with increased bleeding complications, hospital 
records of all patients who underwent percutaneous 
liver biopsy during 56 consecutive months (n = 291) 
were reviewed. Complete information was available 
for 177 inpatient procedures (155 standard, 22 fine 
needle). Overall, the frequency of bleeding complica- 
tions in patients with platelet counts 2 50 x 10s/L was 
3.4% (6 of 175), with no significant difference between 
patients with mild hemostatic abnormalities and pa- 
tients with normal parameters. These data suggest that 
prophylactic transfusions may not be necessary. One 
factor was highly associated with bleeding complica- 
tions: a patient diagnosis of malignancy, 14% (7 of 50) 
compared with 0.8% (1 of 127) among other patients 
(P c 0.001). These patients should be monitored 
closely after biopsy. 
McVay PA, Toy PTCY. Lack of increased bleeding after 
paracentesis and thoracentesis in patients with mild co- 
agulation abnormalities. Transfusion 1991;31: 164-1 7 1. 
ABSTRACT 
To determine whether untreated mild coagulopathy 
in patients with no evidence of clinical bleeding is 
associated with an increased risk of hemorrhage after 
paracentesis or thoracentesis, retrospective exami- 
nation was conducted of 608 consecutive procedures 
for which prothrombin time (PT), partial thrombo- 
plastin time (PTT), platelet (Plt) counts, and prepro- 
cedure and postprocedure hemoglobin concentrations 
were available. There was no increased bleeding in 
patients with mild to moderate coagulopathy (defined 
as PT or PTT up to twice the midpoint normal range or 
plt count of 50 to 99 x los per pL [50-99 x 108iL1). 
However, patients with markedly elevated serum cre- 
atinine levels (6.0 to 14.0 mg/dL [530-1240 kmol/Ll) had 
a significantly greater average hemoglobin loss 
( -0.82 f 1.3 g/dL [ -8 f 13 a], n = 11) than patients 
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withnormal serum creatinine levels ( - 0.12 2 0.88 g/dL 
1-1 2 9 gLl, n = 450) (p = 0.011). Overall, the fre- 
quency of bleeding complications requiring red cell 
transfusions was very low: 0.2 percent of events. The 
most common diagnosis for patients who had paracen- 
tesis was alcoholic liver disease (72%); for those having 
thoracentesis, it was infection (37%). It can be con- 
cluded that, for these patients, prophylactic plasma or 
platelet transfusions are not necessary. Patients with 
markedly elevated serum creatinine deserve close 
postprocedure observation. 
COMMENTS 
It is almost a truism that patients with liver disease 
bleed, and may bleed severely. This leads to some trepi- 
dation when one is faced with performing an invasive 
procedure such as liver biopsy on a patient with liver 
disease and coagulopathy . Prophylactic plasma or 
platelet transfusions are often ordered before invasive 
procedures are performed in such patients, although 
scant evidence of their effectiveness exists. Moreover, 
increased awareness of the risks of blood transfusion has 
prompted greater conservatism in their use. Thus a need 
exists for the development of guidelines related to  spe- 
cific clinical situations, including correction of coagulop- 
athies before procedures. Recently, McVay and Toy pub- 
lished two studies regarding the risk of bleeding in pa- 
tients with mild coagulopathies undergoing invasive 
procedures, with an eye to determining the value of pro- 
phylactic plasma or platelet transfusion in this setting. 
The first study was a retrospective examination of 
patients at the San Francisco General Hospital under- 
going percutaneous liver biopsies in a 56-mo period. 
Patients who received prophylactic fresh frozen plasma 
or who had active bleeding unrelated to the procedure 
were excluded. A bleeding complication was defined as a 
hemoglobin decrease of 20 gm/L, or more after the 
biopsy, allowing for any transfused blood. In addition, 
clinical evidence of bleeding was sought. Most biopsies 
were performed with Menghini-style Klatskin needles, 
with Tru-Cut and fine needles used occasionally. To 
define the degree of coagulopathy, the measured pro- 
thrombin time (PT) and partial thromboplastin time 
(PTT) were compared with the midpoint and the normal 
range for their laboratory. By the authors’ convention, 
mild coagulopathy was considered to be PT up to 1.5 
times control or PTT up to 2.0 times control. Normal 
platelet counts were considered greater than 
100 x 109/L, with mild thrombocytopenia in the range 
50 to 99 x 109/L and moderate-to-marked thrombocy- 
topenia as counts below that. 
These authors identified 177 eligible patients, who 
were stratified according to degree of coagulopathy. The 
overall frequency of bleeding complications was 4.5% of 
the patients, with 3.4% of the patients requiring RBC 
transfusions. No statistically significant difference in 
bleeding complications was found between patients with 
normal PT or PTT and those with mildly elevated levels. 
In addition, no difference was found between patients 
with normal platelet counts and those with mild throm- 
bocytopenia. Two of 14 patients with moderately pro- 
longed PTT and both patients with moderate-to-marked 
thrombocytopenia bled, but too few patients were 
included in these groups to reach a meaningful con- 
clusion. One factor that was significantly associated with 
postbiopsy bleeding was a diagnosis of malignancy. 
However, because a biopsy is most often performed in 
such patients to establish the presence of malignancy, 
this information usually is not available before the 
procedure. 
The second study, which was of similar design, was of 
patients undergoing paracentesis or thoracentesis in a 
30-mo time period. A total of 608 procedures involved 
395 patients. Of these patients, 51% had alcoholic liver 
disease (the single largest category) or hepatitis. The 
overall rate of bleeding complications in a cohort of 
patients with coagulopathy comparable with those in the 
foregoing study was 3%, and only once was RBC 
transfusion required. Again, the authors found no 
significant difference in bleeding complications between 
patients with normal and those with mild to moderately 
prolonged PT or PTT. Mild-to-moderate thrombocyto- 
penia was also not predictive of bleeding; however, 
kidney failure with creatinine levels greater than 530 
pmoVL (6.0 mg/dl) was significantly associated with 
postbiopsy bleeding, most likely caused by acquired 
platelet dysfunction. In this article, the authors sepa- 
rately considered patients who received prophylactic 
fresh frozen plasma transfusions. Although the 
numbers were small (43 procedures in 35 patients), a 
greater proportion of patients with more severe coagu- 
lopathies was seen; however, the incidence of bleeding 
complications in these patients did not differ from those 
in those patients who did not have transfusions. 
Both these studies may be criticized as being retro- 
spective and involving a relatively small number of 
patients; however, the logistic considerations in per- 
forming a large randomized prospective trial are 
daunting. The authors calculated that to  detect a 
doubling of the complication rate in liver biopsies would 
require 950 patients. Such a study is unlikely to be 
undertaken. The rate of bleeding after liver biopsy was 
higher than reported by others, but this rate may be 
accounted for by the selection of carefully monitored 
inpatients who might be expected to  have higher rates of 
complications and by the relatively liberal definitions of 
bleeding based on hemoglobin concentrations. 
If we cannot use the common indices of coagulation to  
predict bleeding in patients undergoing these invasive 
procedures, can the bleeding time be used? The bleeding 
time is a test with great intuitive appeal. The name 
suggests that it will tell you how long a patient will bleed. 
Unfortunately, the predictive value of the bleeding time 
is open to serious question. In a recent comprehensive 
review, Lind (1) notes that although little evidence exists 
to support using the bleeding time as a predictive 
indicator, it continues to be used as a screening test 
because of medical custom and because it has been 
recommended for many years. In addition we make 
assumptions about the test that may not be warranted. 
These assumptions imply that the skin bleeding time 
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correlates with bleeding at other sites, that it is 
diagnostic and prognostic in von Willebrand’s disease, 
that drugs altering platelet function have a consistent 
effect on the bleeding time and that “surgical” bleeding, 
such as that caused by biopsy, is synonymous with 
“clinical” bleeding. Specifically, with respect to liver 
biopsy Lind found only one paper addressing the 
bleeding time in this situation. 
Blake and colleagues (2) studied 100 consecutive 
patients with cirrhosis, 42 of whom had prolonged 
bleeding times, which was defined as more than 10 min 
by the Simplate I1 method. Although not specifically 
stated, all patients apparently underwent liver biopsy, 
most during a previous admission. Complications of 
biopsy are not discussed, but because the bleeding time 
was measured at least 10 days after any bleeding 
episode, it seems unlikely that any serious postbiopsy 
bleeding occurred. They found that of the parameters 
they measured only serum bilirubin and platelet count 
were independently correlated with bleeding time. 
Fourteen patients had prolonged bleeding times despite 
normal platelet counts. These authors, citing other 
authorities, consider a platelet count of greater than 
80 x 109/L and PT less than 17 sec to be “safe limits” 
for performing percutaneous liver biopsy, criteria that 
seem overly conservative in light of the studies of McVay 
and Toy. The authors also recommend that “before 
having invasive procedures patients with raised bili- 
rubin concentrations or poor hepatic function should 
have their bleeding time measured,’’ but they do not 
suggest how this information is to be used in planning 
the procedure. Indeed, from their data, if a normal 
bleeding time and their “safe limits” are used as 
selection criteria, only 29% of patients with cirrhosis 
may have biopsies without risk of hemorrhage. Although 
it is interesting that many cirrhotic patients have an 
unexpected prolonged bleeding time, it clearly is of little 
value in assessing the need for prophylactic transfusion 
before invasive procedures. 
When should one administer prophylactic blood 
products to patients with liver disease? The jury is still 
out; however, it appears that even though we have no 
reliable means of predicting who will bleed after an 
invasive procedure, mild-to-moderate coagulopathy 
seems to pose little, if any, increased risk of bleeding. 
Therefore we may conclude the prophylactic plasma or 
platelet transfusions, with their attendant hazards, are 
not indicated in this setting. 
ROBERTSON D. DAVENPORT, M.D. 
Blood Bank and Transfusion Service 
The University of Michigan Hospitals 
Ann Arbor, Michigan 481 09-0054 
REFERENCES 
1. Lind SE. The bleeding time does not predict surgical bleeding. Blood - - 
1991;77:2547-2552. 
2. Blake JC. Sureneers D. Grech P. McCormick PA. McIntvre N. , .  - 
Burroughs AK. Bleeding time in patients with hepatic cirrhosis: 
BMJ 1990;301:12-15. 
CHOLESCINTIGRAPHY IN ACALCULOUS BILIARY 
PAIN: IF ABNORMAL, SHOULD 
CHOLECYSTECTOMY FOLLOW? 
Yap L, Wycherley AG, Morphett AD, Toouli J .  Acalculous 
biliary pain: cholecystectomy alleviates symptoms in 
patients with abnormal cholescintigraphy . Gastroenter- 
ology 1991;101:786-793. 
ABSTRACT 
A 45-minute infusion of an octapeptide of cholecys- 
tokinin (Kinevac; Squibb Diagnostics, New Brunswick, 
NJ) was used to measure the gallbladder ejection 
fraction during cholescintigraphy in 40 normal volun- 
teers. Cholecystokinin cholescintigraphy was shown to 
be a reproducible test. The maximum mean gallbladder 
ejection fraction occurred 15 minutes after cholecys- 
tokinin infusion and was 74.5% f 1.9% (mean -+ SEM). 
A gallbladder ejection fraction >40% (mean - 3SD) 
was arbitrarily defined to be normal. The gallbladder 
ejection fraction test was then used to identify patients 
with acalculous biliary symptoms who may respond to 
cholecystectomy. A total of 103 patients was tested; 21  
had abnormal gallbladder ejection fractions and were 
randomized into two groups, cholecystectomy or no 
operation. These patients were followed up symptom- 
atically at 3-month intervals for 13-54 months (mean, 
34 months). Of the 11 patients who underwent chole- 
cystectomy, 10 (91%) lost their symptoms and 1 im- 
proved. Of the 10 patients in the group that did not 
undergo surgery, all continued to be symptomatic, 2 of 
whom requested cholecystectomy after 13 and 24 
months, respectively. Of the 13 gallbladders obtained 
from surgery, 12 showed evidence of chronic cholecys- 
titis, muscle hypertrophy, and/or narrowed cystic duct. 
A normal gallbladder ejection fraction was recorded in 
82 patients, and further treatment was left to the 
discretion of their referring clinician. On follow-up, 50 
patients were asymptomatic and 10 were symptomatic 
without specific treatment of the biliary tract; 14 
underwent cholecystectomy, 8 of whom were asymp- 
tomatic. Pathological abnormalities were recorded in 6 
of the removed gallbladders. It is concluded that the 
gallbladder ejection fraction obtained after a 45- 
minute infusion of cholecystokinin during cholescin- 
tigraphy is a reproducible measure of gallbladder 
emptying, and that cholecystectomy alleviates the 
biliary-type pain of patients with a reduced gallbladder 
ejection fraction. 
COMMENTS 
Chronic right upper quadrant pain without gallstones, 
usually identified as “acalculous biliary pain,” has been 
clinically difficult to define in the absence of gallstones. 
The advent of more simplified surgery in the form of 
laparoscopic cholecystectomy presents, perhaps, too 
easy an alternative to a challenging question: what test 
will detect subtle gallbladder-biliary tract disease and 
predict a favorable outcome from surgery? 
The prospective study by Yap et al. would indicate that 
eholecystokinin (CCK) cholescintigraphy is the answer. 
Using a standard infusion of CCK-8 (9 ngkghr) for 45 
min in 108 patients considered to have biliary-type pain, 
21 were found to have a gallbladder ejection fraction less 
